What top creators are saying about Moderna, Inc.(MRNA)— Page 2

Its stock was said to be down about 90%, illustrating that public benefits from a technology do not guarantee durable shareholder returns. The company has discussed using AI to support drug development and testing, but no specific recommendation or price target was given.

The speaker disclosed that he was still short and reacted negatively to the stock being at $210, but provided no further short thesis.

Moderna rose about 12% and was noted as a recent Nasdaq-100 inclusion. Healthcare-sector strength was suggested as a possible factor, but no company-specific cause or thesis was established.

The speaker expressed dissatisfaction with Moderna being at 210 but provided no forecast or clear directional view.

A speaker recounted a successful short trade at the market open, but gave no rationale or outlook on the company's prospects.

Described as exceptionally volatile; a move higher was characterized as a good short opportunity despite the stock rising to about $213–$216.

Positive results renewed investor interest, but further development, regulatory approval, and commercialization are necessary before results establish a durable turnaround.

Moderna was mentioned briefly with no specific analysis or recommendation.

A speaker expressed frustration about Moderna being at 210 while discussing losses; no forecast or recommendation was provided.

Martin said he was short, citing increased competition as many companies could now make the relevant products; no price target or specific catalyst was provided.

The speaker called the stock overvalued and noted that it was declining during the session.

Mentioned hypothetically in a discussion about pharmaceutical companies potentially being slow to build AI teams. The transcript did not discuss Moderna's own strategy or financial outlook.

AI-driven drug discovery could challenge established pharmaceutical companies that fail to build AI capabilities, though no company-specific forecast was given.

A speaker said they were short and described being liquidated on part of that position. Moderna was falling amid a possible reversal in the AI-biotech rally, though gains in the stock were also said to have offset Seagate losses.

The speaker said he remained short and was frustrated with the stock's trading around $210, but provided no supporting thesis.

The speaker called Moderna a short and said the stock could continue falling, but provided no detailed supporting analysis. A $200 comment appeared in chat and was not established as a formal price target.

Mentioned in passing without specific investment analysis or a price target.

Moderna's data at the ESMO meeting were flagged as something to watch, without discussion of results or a stock view.

The host was short, characterized the stock as declining after an unjustified rally, and mentioned a leveraged short position that had been liquidated.

Moderna rose amid discussion of a suspected disease outbreak, but the host dismissed the move as a reason to return to pandemic-era investment positioning.

The host expected the stock to continue downward unless COVID returned, while noting that upcoming ESMO data and COVID-related developments could change the outlook.

The speaker discussed trading in and out of a short position and noted that volatility can create opportunities, but a large short can be difficult to exit; no current recommendation is given.

Briefly described as down on the day, with no company-specific news, investment thesis, or recommendation.

The speaker described Moderna as his largest short, citing faded COVID demand, its cash position, and a lack of important news in his view; $191 was his average short price, not a target.

The stock was noted as down, but no explanation or recommendation was provided.

Its addition to the Nasdaq-100 could attract attention, but the transcript did not provide a long-term investment view.

Despite a roughly 7% decline after a Citi downgrade, the speaker considered a short-term long based on heavy short interest and momentum, while expressing no long-term endorsement of the valuation.

The speaker called Moderna a good short but did not explain the thesis or provide a target.

The speaker saw a downtrend and possible double-top chart pattern, but offered no fundamental analysis and treated the observation tentatively.

The speaker made quick trading profits in Moderna and observed that it had fallen from its highs, emphasizing squeeze-driven volatility and reversal risk rather than a long-term thesis.

Shares fell about 7% after a reported Citi downgrade. A possible short-term rebound was discussed based on short interest and momentum, but the speaker said the stock was overvalued and did not want to be long.

Wood said a major one-day stock gain made sense if Moderna's cancer-vaccine work and what appeared to be approved were as significant as believed, while emphasizing regulatory, reimbursement, and execution challenges.

The discussion pointed to potential opportunity from reported cancer-vaccine developments and AI-enabled healthcare, conditional on the results being validated and approvals secured. No price target was provided, and regulatory, reimbursement, and execution risks remain.

The host made quick trading profits and considered shorting again if the stock rallied, but noted that healthcare stocks in a squeeze can cool off and then rally again.

Mentioned hypothetically as an analogy about government treatment of companies, with no assessment of its products, financials, or outlook.

One speaker said they were short Moderna and would short more. The comments described successful short-term trading but gave no specific rationale for the current bearish position.

Mentioned only in passing; no company-specific investment view was offered.

The speaker discussed prices around $199–$208 and his past short position, but gave no investment thesis.

Moderna was up about 2% in a brief market update without further investment analysis.

The speaker described trading Moderna on both the long and short sides amid volatility, without expressing a lasting directional view. Prices around $190 and $208 were trading references, not targets.

The stock's price movement was noted, but no new fundamental catalyst was discussed.

The speaker covered a short position but intended to short the stock again, expressing a bearish trading view. He noted that forced short covering could also cause a sharp rally.

The speaker remained short and traded in and out of the position, while acknowledging the stock's persistent strength.

Shkreli said he had previously shorted Moderna and wanted to re-establish the short. He characterized it as a crowded hedge-fund short, warning that position reductions could move the share price independently of fundamentals.

The speaker said they were shorting more Moderna, but provided no thesis, catalyst, or price target.

The speaker remarked that Moderna was up and said to short it, but offered no supporting thesis or time horizon.

Shorting Moderna was discussed, but the stock around $180 was described as pressuring short sellers; the directional comments were inconsistent.

Highlighted in the context of AI application themes and broad market rally expectations.

Accelerating pipeline progress in cancer treatments and AI-driven computational drug discovery offers asymmetric upside potential supported by multi-billion-dollar therapeutic outcomes.

Faces an urgent 6-to-12-month window to integrate frontier AI into its biological datasets or risk margin compression and pipeline obsolescence to lower-cost AI-native biotech competitors.